News | December 31, 2025
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The plant is expected to enhance regional supply capabilities
The new facility is expected to generate 500-600 new jobs in the region
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Future of manufacturing lies in mobility based manufacturing
Subscribe To Our Newsletter & Stay Updated
